Enpatoran for adults with skin lupus, with or without systemic disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This global, multicenter Phase 3 study gives participants either enpatoran tablets or placebo alongside standard of care for 24 weeks to measure effects on active cutaneous lupus manifestations. Participants are followed for up to 35 weeks with clinic visits every four weeks and a telemedicine contact at Week 2. The trial enrolls adults with documented discoid, subacute, or acute cutaneous lupus, including those with systemic lupus who meet EULAR/ACR 2019 criteria. Safety and skin-specific outcomes will be compared between groups to determine whether TLR7/8 inhibition by enpatoran improves skin disease.

Why it matters

Who can join: the full rules

Inclusion Criteria

* Vaccinations are up to date according to local guidelines/recommendations. Recombinant zoster vaccination is encouraged but not mandatory.
* Participants with diagnosis of Discoid Lupus Erythematosus (DLE) and/or Subacute Cutaneous Lupus Erythematosus (SCLE) documented in medical history, with or without Systemic Lupus Erythematosus (SLE).
* Participants with active Acute Cutaneous Lupus Erythematosus (ACLE) as sole cutaneous manifestations is allowed in the presence of SLE and should be present for at least 6 weeks prior to the Screening visit.
* Participants with diagnosis of SLE fulfilling the European Alliance of Associations for Rheumatology (EULAR)/American College of Rheumatology (ACR) 2019 classification criteria, must have active DLE and/or SCLE and/or ACLE.

For participants with SLE:

* Participants with diagnosis of SLE and fulfill EULAR/ACR 2019 classification criteria.
* Participants with disease duration (cutaneous disease and, where applicable, SLE) of \>= 6 months from time of diagnosis to Screening.
* Participants with CLASI-A score \>= 8 at Screening and Day 1 visits.
* Other protocol-defined inclusion criteria may apply.

Exclusion Criteria

* Participants with primary diagnosis of autoimmune rheumatic disease (e.g., systemic sclerosis, rheumatoid arthritis) other than Cutaneous Lupus Erythematosus (CLE) and SLE.
* Participants with any condition including dermatological diseases other than cutaneous manifestations of lupus (e.g. psoriasis), any uncontrolled disease (e.g. asthma, chronic obstructive pulmonary disease, interstitial lung disease, bronchiectasis, pulmonary arterial hypertension), or life-threatening manifestations of lupus (e.g. active systemic vasculitis) that in Investigator's or Sponsor/designee's opinion constitutes inappropriate risk or contraindication for participation.
* Participants with drug-induced lupus (SLE or CLE).
* Participants with active lupus nephritis on induction therapy, or induction therapy completed within 3 months of the Screening visit (stable maintenance therapy with either mycophenolate azathioprine or an oral calcineurin inhibitor is allowed).
* Participants with Urine Protein-to-Creatinine Ratio (UPCR) greater than (\>) 339 milligrams per millimole (mg/mmol), and/or estimated Glomerular Filtration Rate (eGFR) less than 40 milliliters per minute per 1.73 square meters of body surface area (mL/min/1.73 m\^2), as calculated by the Modification of Diet in Renal Disease (MDRD) equation.
* Participants with any active signs, symptoms, or diagnoses considered related to Central Nervous System (CNS) lupus within the past 3 months, or any history of uncontrolled seizures.
* Other protocol-defined exclusion criteria may apply.

Where it's running

• Dermatology Research Associates - 300204025
  Los Angeles, California, United States Recruiting
• Cohen Medical Centers
  Thousand Oaks, California, United States Recruiting
• GNP Research at Mark Jaffe, MD
  Cooper City, Florida, United States Recruiting
• Advance Medical Research Center
  Miami, Florida, United States Recruiting
• Diverse Clinical Research LLC
  Miami, Florida, United States Recruiting
• D&H National Research Centers, Inc.
  Tamarac, Florida, United States Recruiting

+24 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Study coordinator: Communication Center
• Email: service@emdgroup.com
• Phone: +49 6151 72 5200

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Long-Term Extension of enpatoran for cutaneous lupus symptoms

  This extension study tests whether continuing enpatoran is safe and helpful for people with skin lupus who completed previous trials, for up to about two years.

  Recruiting Phase 3 EMD Serono · Troy, Michigan · NCT07840287

• Lupus patient registry for better understanding and care

  This study is collecting information from adults with lupus to help improve understanding and care for the disease.

  Recruiting Lupus Foundation of America · Washington D.C., District of Columbia · NCT06927219

• Afimetoran in Adults With Cutaneous Lupus Erythematosus

  This study tests whether the oral medicine afimetoran helps skin lupus in adults who did not respond to antimalarials, by comparing it with a placebo over 24 weeks followed by all participants receiving the drug for 28 more weeks.

  Recruiting at 3 sites Phase 2/3 Beeline Medicines Corporation · San Diego, California and 2 other locations · NCT07881120

• Targeting B cells and plasma cells in lupus with a dual-action antibody

  A new injectable therapy (F182112) will be tested in adults with systemic lupus erythematosus to see if it can help by hitting both CD3 on immune cells and BCMA on B cells and plasma cells.

  Recruiting Phase 1 Shandong New Time Pharmaceutical Co., LTD · Shanghai · NCT07829614

• FT839 therapy for autoimmune diseases

  This trial tests FT839, given alone or with rituximab, to see if it is safe and can help people with certain autoimmune diseases who have not responded to other treatments.

  Recruiting Phase 1/2 Fate Therapeutics · Fullerton, California · NCT07800871

• Triple therapy with voclosporin, MMF and prednisolone in lupus nephritis

  This trial tests whether adding voclosporin to standard lupus nephritis treatment (MMF and prednisolone) early on improves kidney inflammation compared to standard therapy alone.

  Recruiting Phase 4 Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Amsterdam · NCT07760480

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.